101 related articles for article (PubMed ID: 6433325)
1. 186Re-HEDP: a potential therapeutic bone agent.
Weininger J; Ketring AR; Deutsch EA
Nuklearmedizin; 1984 Apr; 23(2):81-2. PubMed ID: 6433325
[TBL] [Abstract][Full Text] [Related]
2. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
3. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
Ketring AR
Int J Rad Appl Instrum B; 1987; 14(3):223-32. PubMed ID: 3117736
[TBL] [Abstract][Full Text] [Related]
4. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
Uehara T; Jin ZL; Ogawa K; Akizawa H; Hashimoto K; Nakayama M; Arano Y
Nucl Med Biol; 2007 Jan; 34(1):79-87. PubMed ID: 17210464
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
[TBL] [Abstract][Full Text] [Related]
6. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
7. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
9. Gastric uptake during Re-186 HEDP bone scintigraphy.
Limouris GS; Skukla SK
Anticancer Res; 1997; 17(3B):1779-81. PubMed ID: 9179234
[TBL] [Abstract][Full Text] [Related]
10. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
11. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
[TBL] [Abstract][Full Text] [Related]
12. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
Hauswirth AE; Palmedo H; Dierke-Dzierzon C; Biersack HJ; Krebs D
Zentralbl Gynakol; 1998; 120(2):83-6. PubMed ID: 9531713
[TBL] [Abstract][Full Text] [Related]
13. Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
Hsieh BT; Hsieh JF; Tsai SC; Lin WY; Wang SJ; Ting G
Nucl Med Biol; 1999 Nov; 26(8):973-6. PubMed ID: 10708313
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
16. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
[TBL] [Abstract][Full Text] [Related]
17. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP.
Samaratunga RC; Thomas SR; Hinnefeld JD; Von Kuster LC; Hyams DM; Moulton JS; Sperling MI; Maxon HR
J Nucl Med; 1995 Feb; 36(2):336-50. PubMed ID: 7830140
[TBL] [Abstract][Full Text] [Related]
18. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
19. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine.
Deutsch E; Libson K; Vanderheyden JL; Ketring AR; Maxon HR
Int J Rad Appl Instrum B; 1986; 13(4):465-77. PubMed ID: 3793504
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
